我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

TLR4在病理性心脏重构中的作用(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2017年第4期
页码:
487-490
栏目:
综述
出版日期:
2017-02-25

文章信息/Info

Title:
Role of Toll like receptor 4 in pathological cardiac remodeling
作者:
彭建业1; 2; 3; 黄 鹤1; 2; 3
武汉大学：1.人民医院心内科，2.心血管病研究所；3.心血管病湖北省重点实验室，湖北 武汉 430060
Author(s):
PENG Jian-ye1; 2; 3;  HUANG He1; 2; 3
1.Department of Cardiology, Renmin Hospital, 2.Cardiovascular Research Institute, Wuhan University; 3.Hubei Key Laboratory of Cardiology, Wuhan 430060, Hubei, China
关键词:
Toll样受体4; 信号通路; 病理性心脏重构
Keywords:
Toll-like receptor 4;  signaling pathways;  pathological cardiac remodeling
分类号:
R364.3
DOI:
-
文献标识码:
A
摘要:
Toll样受体（Toll like receptors，TLRs）是一类跨膜受体家族，在先天性免疫反应和获得性免疫反应中都发挥关键作用。TLR4是最早被发现的 TLR，能识别脂多糖和器官损伤后释放的内源性配体。越来越多的研究证实，TLR4及其介导的信号通路与病理性心脏重构密切相关。本文系统综述了TLR4在压力超负荷或高血压所致心脏重构、缺血/再灌注（I/R）或心肌梗死（MI）后心脏重构和糖尿病心脏重构中的作用及相关机制的研究进展。
Abstract:
Toll-like receptors (TLRs) are a family of transmembrane receptors that play a key role in both innate and acquired immunity responses. The TLR first discovered is TLR4 and it recognizes lipopolysaccharides and endogenous ligands released after organ injury. A growing body of studies suggest that TLR4 and TLR4-mediated signaling pathways are closely related to pathological cardiac remodeling. This article systematically reviews current studies on the role and related mechanisms of TLR4 in pathological cardiac remodeling, which is caused by pressure overload or high blood pressure, by ischemia/reperfusion (I/R) or myocardial infarction (MI) and by diabetes.

参考文献/References

[1]Heusch G,Libby P,Gersh B,et al.Cardiovascular remodelling in coronary artery disease and heart failure[J].Lancet, 2014,383(9932):1933-1943.
[2]Kawai T,Akira S.The role of pattern-recognition receptors in innate immunity:update on Toll-like receptors[J].Nature immunology,2010,11(5):373-384.
[3]Sabroe I,Read RC,Whyte MK,et al.Toll-like receptors in health and disease: complex questions remain[J].Journal of immunology,2003,171(4):1630-1635.
[4]O' Neill LA.The interleukin-1 receptor/Toll-like receptor superfamily:10 years of progress[J].Immunol Rev,2008,226:10-18.
[5]Medzhitov R,Preston-Hurlburt P,Janeway CA Jr.A human homologue of the Drosophila Toll protein signals activation of adaptive immunity[J].Nature,1997,388(6640):394-397.
[6]Beutler B,Rehli M.Evolution of the TIR,tolls and TLRs:functional inferences from computational biology[J].Curr Top Microbiol Immunol,2002,270:1-21.
[7]Frantz S,Ertl G,Bauersachs J.Mechanisms of disease:Toll-like receptors in cardiovascular disease[J].Nat Clin Pract Cardiovasc Med,2007,4(8):444-454.
[8]Ehrentraut H,Weber C,Ehrentraut S,et al.The toll-like receptor 4-antagonist eritoran reduces murine cardiac hypertrophy[J].Eur J Heart Fail,2011,13(6):602-610.
[9]Echem C,Bomfim GF,Ceravolo GS,et al.Anti-toll like receptor 4(TLR4)therapy diminishes cardiac remodeling regardless of changes in blood pressure in spontaneously hypertensive rats(SHR)[J].Int J Cardiol,2015,187:243-245.
[10]Topkara VK,Evans S,Zhang W,et al.Therapeutic targeting of innate immunity in the failing heart[J].J Mol Cell Cardiol,2011,51(4):594-599.
[11]Liu ZW,Wang JK,Qiu C,et al.Matrine pretreatment improves cardiac function in rats with diabetic cardiomyopathy via suppressing ROS/TLR-4 signaling pathway[J].Acta Pharmacol Sin,2015,36(3):323-333.
[12]Dong B,Qi D,Yang L,et al.TLR4 regulates cardiac lipid accumulation and diabetic heart disease in the nonobese diabetic mouse model of type 1 diabetes[J].Am J Physiol Heart Circ Physiol,2012,303(6):H732-H742.
[13]O' Neill LA,Bowie AG.The family of five:TIR-domain-containing adaptors in Toll-like receptor signalling[J].Nat Rev Immunol,2007,7(5):353-364.
[14]Gay NJ,Symmons MF,Gangloff M,et al.Assembly and localization of Toll-like receptor signalling complexes[J].Nat Rev Immunol,2014,14(8):546-558.
[15]Singh MV,Swaminathan PD,Luczak ED,et al.MyD88 mediated inflammatory signaling leads to CaMKII oxidation, cardiac hypertrophy and death after myocardial infarction[J].J Mol Cell Cardiol,2012,52(5):1135-1144.
[16]Heineke J,Molkentin JD.Regulation of cardiac hypertrophy by intracellular signalling pathways[J].Nat Rev Mol Cell Biol,2006,7(8):589-600.
[17]Bernardo BC,Weeks KL,Pretorius L,et al.Molecular distinction between physiological and pathological cardiac hypertrophy:Experimental findings and therapeutic strategies[J].Pharmacol Ther,2010,128(1):191-227.
[18]Ha T,Li Y,Hua F,et al.Reduced cardiac hypertrophy in toll-like receptor 4-deficient mice following pressure overload[J].Cardiovasc Res,2005,68(2):224-234.
[19]Ha T,Hua F,Li Y,et al.Blockade of MyD88 attenuates cardiac hypertrophy and decreases cardiac myocyte apoptosis in pressure overload-induced cardiac hypertrophy in vivo[J].Am J Physiol Heart Circ Physiol,2006,290(3):H985-H994.
[20]Dange RB,Agarwal D,Masson GS,et al.Central blockade of TLR4 improves cardiac function and attenuates myocardial inflammation in angiotensin II-induced hypertension[J].Cardiovasc Res,2014,103(1):17-27.
[21]Vicencio JM,Yellon DM,Sivaraman V,et al.Plasma exosomes protect the myocardium from ischemia-reperfusion injury[J].J Am Coll Cardiol,2015,65(15):1525-1536.
[22]Riad A,Jager S,Sobirey M,et al.Toll-like receptor-4 modulates survival by induction of left ventricular remodeling after myocardial infarction in mice[J].J Immunol,2008,180(10):6954- 6961.
[23]Timmers L,Sluijter JP,Van Keulen JK,et al.Toll-like receptor 4 mediates maladaptive left ventricular remodeling and impairs cardiac function following myocardial infarction[J].Circ Res,2008,102(2):257-264.
[24]Louwe MC,Karper JC,de Vries MR,et al.RP105 deficiency aggravates cardiac dysfunction after myocardial infarction in mice[J].Int J Cardiol,2014,176(3):788-793.
[25]Haas B,Leonard F,Ernens I,et al.Adenosine reduces cell surface expression of toll-like receptor 4 and inflammation in response to lipopolysaccharide and matrix products[J].J Cardiovasc Transl Res,2011,4(6):790-800.
[26]Satoh M,Shimoda Y,Maesawa C,et al.Activated toll-like receptor 4 in monocytes is associated with heart failure after acute myocardial infarction[J].Int J Cardiol,2006,109(2):226-234.
[27]Zhang Y,Peng T,Zhu H,et al.Prevention of hyperglycemia-induced myocardial apoptosis by gene silencing of Toll-like receptor-4[J].J Transl Med,2010,8:133.
[28]Tao A,Song J,Lan T,et al.Cardiomyocyte-fibroblast interaction contributes to diabetic cardiomyopathy in mice:Role of HMGB1/TLR4/IL-33 axis[J].Biochim Biophys Acta,2015,1852(10 Pt A):2075-2085.

备注/Memo

备注/Memo:
收稿日期：2016-08-29.基金项目：湖北省科技支撑计划项目资助（2013BCB013）；国家自然科学基金项目资助（81270249，81570306） 通讯作者：黄鹤，教授，主要从事心律失常的基础和临床研究 Email：huanghe1977@whu.edu.cn 作者简介：彭建业，博士生 Email：pengshu1234@163.com
更新日期/Last Update: 1900-01-01